The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Compared with placebo, evaluate the effects and safety of Ulinastatin(UTI) added to
conventional treatment for ARDS; Evaluate the dose response relationship of Ulinastatin for
ARDS.
Phase:
Phase 2
Details
Lead Sponsor:
Techpool Bio-Pharma Co., Ltd.
Collaborator:
The First Affiliated Hospital of Guangzhou Medical University